CClinicalTrials.gg
RecruitingNCT07276152TechnOXYUpdated Feb 13, 2026

Plasma Oxytocin Changes in Response to Music Modified by Sonic Augmentation Technology

An interventional study of sonic augmentation technology in Sonic Augmentation Technology, sponsored by University Hospital, Basel, Switzerland. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The investigator aim to investigate wheather music modified by sonic augmentation technology can produce increasing oxytocin levels with minimal to no side effects in a highly standardized setting

02

Conditions studied

  • Sonic Augmentation Technology

Keywords

  • Arginine Vasopressin Deficiency
  • oxytocin
  • diabetes insipidus
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Part 1:

Inclusion Criteria:

  • Adult healthy controls
  • No medication, except hormonal contraception

Exclusion Criteria:

  • Participation in a trial with investigational drugs within 30 days
  • Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
  • Consumption of alcoholic beverages >15 drinks/week
  • Tobacco smoking >10 cigarettes/day
  • Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
  • Psychotic disorder in first-degree relatives
  • Pregnancy and breastfeeding

Part 2:

Inclusion Criteria:

  • Confirmed diagnosis of AVP-Deficiency
  • Age ≥ 18 years

Exclusion Criteria:

  • Participation in a trial with investigational drugs within 30 days
  • Illicit substance use (except for cannabis) more than 10 times in lifetime or any time within the previous two months
  • Consumption of alcoholic beverages >15 drinks/week
  • Tobacco smoking >10 cigarettes/day
  • Current or previous major psychiatric disorder (e.g., major depression, schizophrenia spectrum disorder)
  • Psychotic disorder in first-degree relatives
  • Pregnancy and breastfeeding
04

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Sonic augmentation technology (SAT) - placebo music

    Participants will listen to music enhanced with SAT in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to placebo music

    Other: sonic augmentation technology

  • Experimental
    placebo music- sonic augmentation technology (SAT) music

    Participants will listen to placebo in their first study visit. After a washout-phase of at least 20 hours they will come to a second study visit and they will listen to music enhanced with SAT

    Other: sonic augmentation technology

  • Experimental
    Sonic augmentation technology (SAT) in patients

    Patients have one study visit listening to SAT

    Other: sonic augmentation technology

Interventions

  • Othersonic augmentation technology

    Participants/ patients listen to music enhanced with sonic aumentation technology

05

What researchers measure

Primary outcomes

  1. Change in oxytocin levels in healthy adults after listening to SAT enhanced music vs. placebo music

    Oxytocin release in response to music enhanced with SAT in healthy participants compared to oxytocin release in response to placebo stimulation in healthy participants

    Time frame: up to 30 min

  2. Change in oxytocin levels in patients with AVP-deficiency after listening to SAT enhanced music

    baseline is defined as 100% of the initial value, in patients with AVP-Deficiency. Any changes will be expressed as a percentage relative to this baseline. Maximum oxytocin level observed between baseline and 30 minutes will be determined.

    Time frame: up to 30 minutes

Secondary outcomes

  1. Area under the concentration time curve in plasma oxytocin

    will be assessed for music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  2. Peak change in plasma oxytocin

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  3. Time course of plasma oxytocin levels

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  4. Time course of plasma copeptin

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  5. Time course of plasma cortisol

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  6. Time course of plasma neurophysin-1

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  7. Time course of other pituitary hormones/biomarkers

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT

    Time frame: up to 30 minutes

  8. Subjective/emotional effects assessed on numeric rating scale (NRS)

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 30 min after listening to SAT. NRS will be presented as a range from 0 to 10 marked with "not at all" on the left and "extremely" on the right. The following NAS will be used: "any effect", "good effect", "bad effect", "liking", "high", "happy", "fear", "stimulated", "feeling close to others", "concentration", "thinking", "open", "trust", "want to be with other people", "loss of sense of time", and "the boundaries between myself and my surroundings seemed to blur".

    Time frame: up to 30 minutes

  9. Anxiety level using State-Trait Anxiety Inventory (STAI - State)

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency. Baseline (before lisening to SAT) to 35 min after listening to SAT. Based on responses to 20 items, with scores ranging from 1 ("almost never") to 4 ("almost always"), a total score is calculated. The total trait score (STAI-T) ranges from 20 to 80, with higher scores indicating more pronounced anxiety and scores.

    Time frame: up to 35 minutes

  10. Frequency of specific body stress reactions using the Body Perception Questionnaire Short Form (BPQ-SF)

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 50 min after listening to SAT. The BPQ-SF will be used to assess the frequency of specific body stress reactions in organs that are innervated by the autonomic nervous system (ANS). This study uses the Short Form (SF), totaling 46 items ranked from 1 (Never) to 5 (Always) to measure the frequency of specific body stress reactions. Though each unique part of the body may have its own reason for activation, the parts are linked by the ANS, a brain-body network that responds to everyday stress. Combined scores from organs throughout the body provide a measure of autonomic stress response patterns.

    Time frame: up to 50 minutes

  11. Recognition of emotions and body expressions in the EmBody/EmFace task

    will be assessed music enhanced with SAT compared to placebo music in healthy adults and for music enhanced with SAT in patients with AVP-Deficiency Baseline (before lisening to SAT) to 35 min after listening to SAT. The EmBody and EmFace subtasks comprise each of 42 stimuli showing body or facial expressions of angry, happy, or neutral affect (14 clips per emotion, half in front view and half in half-profile side view from the left). Stimuli last 1.5 seconds at 24 frames per second and are geometrically and optically standardized to prevent biases induced by ethnic cues (e.g., hair or skin tone) or clothing. Item order is pseudorandom to prevent sequence effects and was determined using the following constraints: the same emotion is shown no more than twice in a row; the same view per emotion is not shown consecutively (i.e., no angry-front, angry-front).

    Time frame: up to 35 minutes

  12. Assessment of blood pressure

    safety assessment of systolic and diastolic blood pressure. Safety outcomes will be summarized using descriptive statistics.

    Time frame: up to 40 minutes

  13. Assessment of heart rate

    Saftey assessment of heart rate. Safety outcomes will be summarized using descriptive statistics.

    Time frame: up to 40 minutes

  14. Assessment of body temperature

    Safety assessment of body temperature. Safety outcomes will be summarized using descriptive statistics.

    Time frame: up to 40 minutes

  15. Assessment of plasma potassium

    Safety assessment of plasma potassium. Safety outcomes will be summarized using descriptive statistics

    Time frame: up to 30 minutes

  16. Assessment of plasma sodium

    Safety assessment of plasma sodium. Safety outcomes will be summarized using descriptive statistics.

    Time frame: up to 30 minutes

06

Study locations

1 of 1 sites recruiting
  • University Hospital Basel
    Basel, 4031, Switzerland
    • Mirjam Christ-Crain, Prof. · Contact · Mirjam.Christ-Crain@usb.ch · +41 61 265 25 25
    • Mirjam Christ-Crain, Prof. · Principal investigator
    Recruiting
07

Registry details

Key details

Study ID
NCT07276152
Lead sponsor
University Hospital, Basel, Switzerland
Responsible party
Sponsor
First posted
Dec 10, 2025
Start date
Jan 9, 2026
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Feb 13, 2026

Study contacts

Mirjam Christ-Crain, Prof.
Contact
Mirjam.Christ-Crain@usb.ch
+41 61 265 25 25
Mirjam Christ-Crain, Prof.
principal investigator · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion